Stay updated with breaking news from Ramp 201. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape. ....